Cargando…
Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
In the US, obesity rates are increasing greatly. The Centers for Disease Control and Prevention estimates that 68.5% of Americans, including 63.9% of adult women older than 20 years, are overweight (body mass index between 25 kg/m(2) and 29.9 kg/m(2)) or obese (body mass index >30 kg/m(2)). In li...
Autores principales: | Lam, Clarissa, Murthy, Amitasrigowri S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683152/ https://www.ncbi.nlm.nih.gov/pubmed/29386945 http://dx.doi.org/10.2147/OAJC.S84097 |
Ejemplares similares
-
Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera
por: Halpern, Vera, et al.
Publicado: (2021) -
Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer*
por: Bloom, H. J. G.
Publicado: (1971) -
Incidental Finding of Persistent Hydatidiform Mole in an Adolescent on Depo-Provera
por: Akinlaja, Olukayode, et al.
Publicado: (2016) -
Diabetes insipidus in a patient with PCOS treated with Depo-Provera
por: Martinez, Amanda I, et al.
Publicado: (2022) -
Precipitous Delivery Masquerading as Biliary Colic in the Setting of Depo-Provera® Failure
por: Chang, Allen D, et al.
Publicado: (2020)